From: Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients
ICIs Therapy
n = 26
Non-ICIs Therapy
n = 14
P value
Active tuberculosis
3
0
0.186
Latent infection
23
14